
Feel Good Knees Introduces 'Knee Self-Restoration Ritual' Backed by Stanford Orthopedic Research on Natural Cartilage Healing
For decades, doctors claimed that cartilage couldn't heal itself. But recent studies—led in part by Dr. Constance Chu of Stanford University—are challenging that belief. Using MRI imaging, researchers have observed signs of natural knee joint regeneration, inspiring new approaches to non-invasive recovery. One such approach, featured in the Feel Good Knees system, is gaining traction among active adults and seniors looking to avoid surgery and reclaim pain-free movement. This 5-minute 'Knee Self-Restoration Ritual' is now being hailed as a gentle, science-guided method for unlocking the body's hidden healing potential.
To see how this gentle routine is changing the way knee health is approached, visit the official Feel Good Knees Self-Healing System resource page.
Why Interest in 'Knee Self-Healing' Is Surging in 2025
In 2025, more adults than ever are rethinking how they approach knee pain. A combination of rising surgery costs, drug-related risks, and breakthrough science is fueling public demand for safer, simpler alternatives that focus on the body's natural ability to heal.
Searches for terms like 'natural knee pain relief,' 'cartilage regeneration,' and 'avoid knee surgery' have exploded on Google, while platforms like Reddit, TikTok, and YouTube are flooded with user-driven discussions around joint health, body alignment, and pain-free movement at any age.
Why the sudden shift?
For starters, many are becoming disillusioned with traditional solutions. NSAIDs—commonly used anti-inflammatory medications—are now under increasing scrutiny. According to the American Journal of Medicine, NSAIDs are linked to over 16,500 deaths each year from gastrointestinal bleeding, while countless others suffer from liver and kidney complications caused by prolonged use【Source: AJM; Singh 1998】.
Surgical options aren't much better. The average knee replacement surgery in the U.S. costs between $30,000 and $50,000, and can leave patients with long recoveries, visible scarring, and recurring discomfort【Source: Healthline; 'What You Need to Know About Knee Surgery'】. And according to research published in Harvard Health , knee replacement implants often need to be replaced again after 10–15 years, creating additional surgeries and financial burdens down the line【Source: Harvard Health Publishing, 2023】.
But perhaps the most exciting reason for this surge in interest is emerging from the scientific community itself.
In a pivotal two-year study published in the Journal of the American Medical Association , researchers tracked 325 patients with knee cartilage degeneration. Using high-resolution MRI technology, they discovered that 37% of patients showed signs of cartilage healing—an outcome previously believed to be impossible. Their conclusion: 'MRI results showed cartilage repair and healing.'【Source: JAMA, 2023】
This finding was further echoed by Dr. Constance Chu, a renowned Stanford Orthopedic Surgeon and Professor, who has led research showing that articular cartilage possesses self-repair capacity under the right mechanical and biological conditions. Her stance directly contradicts decades of conventional wisdom that once damage occurs, it's permanent【Source: Stanford Medicine; Dr. Constance Chu Lab】.
These data points, combined with mounting anecdotal success stories, have created a groundswell. People no longer want to merely 'manage' knee pain—they want to overcome it. And they're now open to exploring simple, non-invasive rituals that support their body's innate healing abilities.
In short, the concept of 'knee self-healing' is no longer pseudoscience—it's a growing global movement, grounded in evidence, and propelled by everyday people who are ready to reclaim their mobility.
Experience the difference a natural approach makes—explore the Feel Good Knees Self-Healing System now.
Feel Good Knees as a Response to This Shift
As millions seek non-invasive alternatives to injections and joint surgeries, one system is quietly leading the conversation: Feel Good Knees.
This 5-minute-per-day method, known as the 'Knee Self-Restoration Ritual,' is designed to work with the body's natural recovery systems—without pills, painful physical therapy, or medical equipment. At the center of this approach is a simple question: what if the knees were never the problem, but rather the neglected victim of poor alignment, restricted mobility, and years of muscle imbalance?
The Feel Good Knees system approaches joint discomfort not as a chronic curse, but as a correctable pattern—one that can be addressed with gentle, science-backed movement protocols.
Developed by fitness educator and medical manual therapy specialist Todd Kuslikis, the program is built for aging adults who want to reclaim control of their mobility from the comfort of home. The system blends therapeutic isometric holds, alignment adjustments, and relaxation-based techniques designed specifically for sore, stiff, or post-surgical knees. No gym memberships. No risky devices. Just five minutes a day in a chair, on the bed, or even while standing.
And its design wasn't random. Kuslikis created the program after watching his own wife suffer through knee pain so severe that it interrupted their daily lives—and even their intimacy. Armed with a background in kinesiology, calisthenics, and injury rehabilitation, he began assembling a toolkit of gentle, proven movements that support circulation, lubrication, and functional knee positioning.
The result: a user-friendly program that doesn't require athleticism, prior experience, or even full mobility to get started.
What makes it resonate so deeply with users is its simplicity. It doesn't promise to 'cure' anyone, nor does it rely on trends or gimmicks. Instead, Feel Good Knees positions itself as a natural response to a broken system—offering hope not through hype, but through self-guided action.
In a market flooded with braces, pills, and quick fixes, Feel Good Knees stands out for its ability to restore not just mobility, but also confidence. It acknowledges the science of self-healing, incorporates modern orthopedic findings, and translates them into a ritual that real people can actually use.
Ready to take control of your knee health?See how others are doing it with the Feel Good Knees program.
What Online Users Are Saying About This Category
Across the internet in 2025, a growing wave of users is challenging the mainstream narrative about joint pain—especially when it comes to aging knees.
From Reddit threads and podcast transcripts to YouTube commentary and TikTok explainers, people of all ages are increasingly skeptical of the traditional 'pill or surgery' approach. What once felt like the default medical advice—NSAIDs, injections, or full joint replacements—is now facing resistance from everyday users who are openly sharing their frustrations and exploring non-invasive alternatives.
On TikTok, videos tagged with #kneepainrelief, #naturalhealing, and #jointmobility now boast millions of views. Creators frequently talk about lifestyle upgrades, posture corrections, and overlooked alignment techniques that have helped them avoid surgery. Others share their experiments with mobility routines, barefoot training, or low-impact movement regimens—all seeking the same goal: pain-free movement without dependency.
Meanwhile, popular podcasts in the health and aging space are dedicating entire episodes to mobility without medication, often highlighting overlooked therapies like isometric protocols, fascia release, and micro-adjustment exercises. Listeners are responding with enthusiasm, echoing sentiments like 'why didn't I hear about this 10 years ago?' and 'my doctor never told me there were alternatives.'
In online review forums and comment sections, one theme is consistent: people want options that are gentle, proven, and accessible from home. There's a growing cultural belief that knees—like skin, muscles, and other tissues—shouldn't be excluded from the body's natural healing intelligence.
The Feel Good Knees Self-Healing System has entered that conversation as a quiet frontrunner. While many systems rely on trends or unproven supplements, this method resonates because it taps into what online users already believe: that less can be more, and that a structured, low-resistance approach might actually work better than anything they've tried before.
For many, it's not about avoiding doctors—it's about finally finding something that aligns with their values and actually fits into their daily lives.
As one long-time wellness forum user put it, 'After all the braces, pills, and pricey gadgets, I can't believe a five-minute technique from a recliner is what finally gave me relief.'
Learn why thousands are turning to this self-healing method—access the Feel Good Knees official guide.
Who Might Gravitate Toward This Product in 2025
In 2025, the desire for pain-free movement isn't limited to athletes or injury recovery patients. It spans a much wider audience—people who are tired of feeling sidelined by discomfort and eager to regain control of their bodies, starting with their knees.
The Feel Good Knees system was designed with these people in mind.
Many are active adults in their 50s, 60s, or 70s who feel youthful at heart, but find their knees limiting their participation in everyday joys—whether it's gardening, golf, or chasing grandkids. These individuals aren't necessarily seeking high-performance results. What they want is freedom: the ability to move confidently, bend easily, and wake up without that familiar throb in their joints.
Others include people who've had surgeries—some successfully, others not—who are looking for a way to support long-term joint health without relying on repeat procedures, follow-up injections, or prescription painkillers.
Then there are those who've been proactive all along. Health-conscious individuals who believe in prevention and mobility longevity. For them, the Feel Good Knees ritual acts as a daily tune-up—gentle, grounded in physiology, and supportive of natural function.
Even younger users, such as former athletes or those recovering from old sports injuries, are turning to this kind of program. Many are discovering that restoring patella alignment, relaxing overworked ligaments, and building low-impact joint strength can provide long-term comfort and stability—especially when done consistently over time.
What unites them all is the mindset: people who aren't waiting around for pain to get worse. They want something simple, structured, and sustainable—without aggressive treatments or synthetic drugs.
Whether you're just beginning to notice stiffness or have been managing knee discomfort for years, the Feel Good Knees system offers a calm, intelligent response to a complex problem. It doesn't demand hours of your time or access to a clinic. Instead, it gives you the tools to take charge of your recovery right from your recliner.
To find out how this at-home system is helping thousands of people step back into life with strength and ease, explore the official Feel Good Knees Self-Healing System today.
Market Category Reflections – Why This Niche Is Expanding
The market for non-invasive pain management, particularly in the realm of joint support, has evolved rapidly in recent years. In 2025, a growing number of consumers are opting out of conventional solutions and exploring alternatives that were once considered fringe—such as fascia manipulation, isometric therapy, or passive alignment-based rituals.
One of the fastest-growing subcategories within this movement is the self-guided, home-based mobility program. Products like Feel Good Knees are thriving not just because they're easier or less expensive—but because they're aligned with a deeper cultural shift.
Today's consumers are more informed than ever. They question the idea that aging automatically leads to immobility. They research. They cross-reference clinical studies. They ask if surgery is truly the only option. And most importantly, they're demanding solutions that don't require them to surrender control of their bodies—or their wallets.
This shift is reflected in keyword trends as well. Search volume for phrases like 'natural knee cartilage support,' 'home knee therapy,' and 'knee healing without surgery' has surged globally. Influencers and wellness practitioners are also fueling the conversation, contributing to what many now recognize as a full-scale category breakout.
Part of this explosion in interest is due to the new wave of research validating the self-healing potential of joints. The 2023 JAMA study documenting 37% cartilage improvement in knees using natural, non-surgical methods has become a landmark reference point in online forums and health communities【Source: JAMA, 2023】.
Additionally, Stanford University orthopedic professor Dr. Constance Chu continues to make headlines for her bold position that 'articular cartilage can heal' under proper conditions【Source: Stanford Medicine, 2023】. This single phrase, echoed across academic publications and interviews, has helped legitimize an entire category of non-invasive knee recovery methods that once existed outside the medical mainstream.
But it's not just science driving the shift—it's demographics.
The number of Americans over 60 continues to climb, and with it, a growing demand for mobility solutions that don't rely on narcotics, joint injections, or surgical implants. As the healthcare system becomes more expensive and overburdened, programs that teach users to restore function naturally—on their own terms—are being embraced as both a medical necessity and a personal empowerment tool.
Feel Good Knees sits squarely in the center of that trend.
It reflects the new definition of wellness: individualized, sustainable, evidence-informed, and low-risk. It also speaks to a larger consumer truth—people no longer want to be patients. They want to be participants in their own recovery.
Take the first step toward pain-free knees—visit the Feel Good Knees Self-Healing System homepage.
Public Debate – Supporters, Skeptics, and the Signals Behind the Buzz
As interest in natural joint healing grows, so too does the conversation surrounding its legitimacy. The Feel Good Knees Self-Healing System has found itself at the center of this expanding debate—welcomed by many, questioned by others, and observed closely by professionals across fields ranging from physical therapy to biohacking.
Supporters of the system point to the growing body of research that validates the potential for cartilage regeneration and biomechanical realignment, even in aging populations. They highlight studies like the 2023 publication in The Journal of the American Medical Association , which showed measurable MRI-documented cartilage improvements in over one-third of participants using non-surgical interventions【Source: JAMA, 2023】. They also cite expert commentary from Stanford Orthopedic Professor Dr. Constance Chu, whose work continues to affirm that knee cartilage may not be as static and unchangeable as once believed【Source: Stanford Medicine】.
Beyond the academic world, practitioners in manual therapy and movement science have voiced support as well. They see routines like Feel Good Knees not as miracle cures, but as structured interventions that restore healthy joint mechanics through cumulative, low-impact input. In this light, the system becomes a tool for long-term maintenance, rather than a quick-fix remedy.
However, not everyone is convinced.
Skeptics warn that some users may overestimate the results or delay needed medical intervention. Critics argue that while natural healing is promising, it must be personalized and carefully monitored—particularly for those with advanced osteoarthritis, surgical complications, or degenerative meniscus damage.
Others raise concerns about the oversimplification of knee biomechanics in popular marketing. They note that joint dysfunction is often multifactorial—impacted by weight, posture, injury history, and even genetics—and that no single solution, however well-designed, should be seen as universal.
But even in these critiques, there is common ground.
Most observers—supportive or skeptical—acknowledge that the system's emphasis on low-risk, low-impact routines is a net positive. The real disagreement lies not in whether such programs should exist, but in how broadly they should be recommended.
What continues to tip the scale in the system's favor is one undeniable factor: user experience.
With over 119,000 users and countless unsolicited testimonials reporting improved comfort, enhanced mobility, and a renewed sense of independence, the public momentum is difficult to ignore.
Even many cautious observers admit that if a program is affordable, easy to follow, and doesn't interfere with conventional treatment, it may provide meaningful benefits—whether through physical stimulation or the psychological empowerment that comes with taking action.
And that may be the most important signal behind the buzz: people want to participate in their own recovery. Not just passively treat symptoms—but actively work toward a better outcome.
Uncover the breakthrough routine helping people move without pain—see what the Feel Good Knees System is all about.
About Feel Good Knees
Feel Good Knees is a mobility-focused wellness program designed to support healthy knees through natural, non-invasive methods. Founded by fitness educator and injury prevention specialist Todd Kuslikis, the brand's core mission is to empower aging adults to regain control of their movement without surgery, pills, or high-intensity exercise.
Rooted in decades of anatomical study, therapeutic movement design, and orthopedic science, the system was developed specifically for seniors and adults dealing with recurring knee pain, stiffness, or joint instability. It combines gentle isometric protocols, alignment-based postural corrections, and fascia-releasing techniques—all structured into a simple, five-minute daily ritual.
What makes the Feel Good Knees approach unique is its intentional accessibility. It requires no special equipment, no athletic background, and no in-person appointments. The system is self-paced, easy to follow, and built to deliver meaningful results from the comfort of home.
The company operates on an education-first philosophy. Every technique is demonstrated via high-definition video and explained in plain language, ensuring users understand not just what to do—but why it works. This teaching-based model reflects the brand's belief that real change happens when users are informed, not just instructed.
Feel Good Knees also incorporates the latest research into joint healing, muscle recruitment, and postural alignment. The program is updated as new science emerges, and remains committed to transparency, user safety, and long-term joint wellness.
Your knees deserve to feel better—discover the Feel Good Knees approach that's changing lives.
Contact
Final Disclaimer
This press release is for informational purposes only. The content herein does not constitute financial, legal, or medical advice. Feel Good Knees is not intended to diagnose, treat, predict, or guarantee any result or outcome. Individual experiences may vary, and outcomes are not assured.
Some links in this release may be promotional in nature and may lead to third-party websites. The publisher or author may receive compensation through affiliate commissions if a purchase is made through these links. This compensation does not affect the price you pay and helps support continued research and content publication.
All statements made about product features, platform strategies, or training content reflect publicly available information, user discussions, or historical trends, and are not endorsed or validated by regulatory bodies. Please perform your own research before making financial, technological, or purchasing decisions.
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Verge
3 hours ago
- The Verge
Google's healthcare AI made up a body part — what happens when doctors don't notice?
Scenario: A radiologist is looking at your brain scan and flags an abnormality in the basal ganglia. It's an area of the brain that helps you with motor control, learning, and emotional processing. The name sounds a bit like another part of the brain, the basilar artery, which supplies blood to your brainstem — but the radiologist knows not to confuse them. A stroke or abnormality in one is typically treated in a very different way than in the other. Now imagine your doctor is using an AI model to do the reading. The model says you have a problem with your 'basilar ganglia,' conflating the two names into an area of the brain that does not exist. You'd hope your doctor would catch the mistake and double-check the scan. But there's a chance they don't. Though not in a hospital setting, the 'basilar ganglia' is a real error that was served up by Google's healthcare AI model, Med-Gemini. A 2024 research paper introducing Med-Gemini included the hallucination in a section on head CT scans, and nobody at Google caught it, in either that paper or a blog post announcing it. When Bryan Moore, a board-certified neurologist and researcher with expertise in AI, flagged the mistake, he tells The Verge, the company quietly edited the blog post to fix the error with no public acknowledgement — and the paper remained unchanged. Google calls the incident a simple misspelling of 'basal ganglia.' Some medical professionals say it's a dangerous error and an example of the limitations of healthcare AI. Med-Gemini is a collection of AI models that can summarize health data, create radiology reports, analyze electronic health records, and more. The pre-print research paper, meant to demonstrate its value to doctors, highlighted a series of abnormalities in scans that radiologists 'missed' but AI caught. One of its examples was that Med-Gemini diagnosed an 'old left basilar ganglia infarct.' But as established, there's no such thing. Fast-forward about a year, and Med-Gemini's trusted tester program is no longer accepting new entrants — likely meaning that the program is being tested in real-life medical scenarios on a pilot basis. It's still an early trial, but the stakes of AI errors are getting higher. Med-Gemini isn't the only model making them. And it's not clear how doctors should respond. 'What you're talking about is super dangerous,' Maulin Shah, chief medical information officer at Providence, a healthcare system serving 51 hospitals and more than 1,000 clinics, tells The Verge. He added, 'Two letters, but it's a big deal.' In a statement, Google spokesperson Jason Freidenfelds told The Verge that the company partners with the medical community to test its models and that Google is transparent about their limitations. 'Though the system did spot a missed pathology, it used an incorrect term to describe it (basilar instead of basal). That's why we clarified in the blog post,' Freidenfelds said. He added, 'We're continually working to improve our models, rigorously examining an extensive range of performance attributes -- see our training and deployment practices for a detailed view into our process.' On May 6th, 2024, Google debuted its newest suite of healthcare AI models with fanfare. It billed 'Med-Gemini' as a 'leap forward' with 'substantial potential in medicine,' touting its real-world applications in radiology, pathology, dermatology, ophthalmology, and genomics. The models trained on medical images, like chest X-rays, CT slices, pathology slides, and more, using de-identified medical data with text labels, according to a Google blog post. The company said the AI models could 'interpret complex 3D scans, answer clinical questions, and generate state-of-the-art radiology reports' — even going as far as to say they could help predict disease risk via genomic information. Moore saw the authors' promotions of the paper early on and took a look. He caught the mistake and was alarmed, flagging the error to Google on LinkedIn and contacting authors directly to let them know. The company, he saw, quietly switched out evidence of the AI model's error. It updated the debut blog post phrasing from 'basilar ganglia' to 'basal ganglia' with no other differences and no change to the paper itself. In communication viewed by The Verge, Google Health employees responded to Moore, calling the mistake a typo. In response, Moore publicly called out Google for the quiet edit. This time the company changed the result back with a clarifying caption, writing that ''basilar' is a common mis-transcription of 'basal' that Med-Gemini has learned from the training data, though the meaning of the report is unchanged.' Google acknowledged the issue in a public LinkedIn comment, again downplaying the issue as a 'misspelling.' 'Thank you for noting this!' the company said. 'We've updated the blog post figure to show the original model output, and agree it is important to showcase how the model actually operates.' As of this article's publication, the research paper itself still contains the error with no updates or acknowledgement. Whether it's a typo, a hallucination, or both, errors like these raise much larger questions about the standards healthcare AI should be held to, and when it will be ready to be released into public-facing use cases. 'The problem with these typos or other hallucinations is I don't trust our humans to review them' 'The problem with these typos or other hallucinations is I don't trust our humans to review them, or certainly not at every level,' Shah tells The Verge. 'These things propagate. We found in one of our analyses of a tool that somebody had written a note with an incorrect pathologic assessment — pathology was positive for cancer, they put negative (inadvertently) … But now the AI is reading all those notes and propagating it, and propagating it, and making decisions off that bad data.' Errors with Google's healthcare models have persisted. Two months ago, Google debuted MedGemma, a newer and more advanced healthcare model that specializes in AI-based radiology results, and medical professionals found that if they phrased questions differently when asking the AI model questions, answers varied and could lead to inaccurate outputs. In one example, Dr. Judy Gichoya, an associate professor in the department of radiology and informatics at Emory University School of Medicine, asked MedGemma about a problem with a patient's rib X-ray with a lot of specifics — 'Here is an X-ray of a patient [age] [gender]. What do you see in the X-ray?' — and the model correctly diagnosed the issue. When the system was shown the same image but with a simpler question — 'What do you see in the X-ray?' — the AI said there weren't any issues at all. 'The X-ray shows a normal adult chest,' MedGemma wrote. In another example, Gichoya asked MedGemma about an X-ray showing pneumoperitoneum, or gas under the diaphragm. The first time, the system answered correctly. But with slightly different query wording, the AI hallucinated multiple types of diagnoses. 'The question is, are we going to actually question the AI or not?' Shah says. Even if an AI system is listening to a doctor-patient conversation to generate clinical notes, or translating a doctor's own shorthand, he says, those have hallucination risks which could lead to even more dangers. That's because medical professionals could be less likely to double-check the AI-generated text, especially since it's often accurate. 'If I write 'ASA 325 mg qd,' it should change it to 'Take an aspirin every day, 325 milligrams,' or something that a patient can understand,' Shah says. 'You do that enough times, you stop reading the patient part. So if it now hallucinates — if it thinks the ASA is the anesthesia standard assessment … you're not going to catch it.' Shah says he's hoping the industry moves toward augmentation of healthcare professionals instead of replacing clinical aspects. He's also looking to see real-time hallucination detection in the AI industry — for instance, one AI model checking another for hallucination risk and either not showing those parts to the end user or flagging them with a warning. 'In healthcare, 'confabulation' happens in dementia and in alcoholism where you just make stuff up that sounds really accurate — so you don't realize someone has dementia because they're making it up and it sounds right, and then you really listen and you're like, 'Wait, that's not right' — that's exactly what these things are doing,' Shah says. 'So we have these confabulation alerts in our system that we put in where we're using AI.' Gichoya, who leads Emory's Healthcare Al Innovation and Translational Informatics lab, says she's seen newer versions of Med-Gemini hallucinate in research environments, just like most large-scale AI healthcare models. 'Their nature is that [they] tend to make up things, and it doesn't say 'I don't know,' which is a big, big problem for high-stakes domains like medicine,' Gichoya says. She added, 'People are trying to change the workflow of radiologists to come back and say, 'AI will generate the report, then you read the report,' but that report has so many hallucinations, and most of us radiologists would not be able to work like that. And so I see the bar for adoption being much higher, even if people don't realize it.' Dr. Jonathan Chen, associate professor at the Stanford School of Medicine and the director for medical education in AI, searched for the right adjective — trying out 'treacherous,' 'dangerous,' and 'precarious' — before settling on how to describe this moment in healthcare AI. 'It's a very weird threshold moment where a lot of these things are being adopted too fast into clinical care,' he says. 'They're really not mature.' On the 'basilar ganglia' issue, he says, 'Maybe it's a typo, maybe it's a meaningful difference — all of those are very real issues that need to be unpacked.' Some parts of the healthcare industry are desperate for help from AI tools, but the industry needs to have appropriate skepticism before adopting them, Chen says. Perhaps the biggest danger is not that these systems are sometimes wrong — it's how credible and trustworthy they sound when they tell you an obstruction in the 'basilar ganglia' is a real thing, he says. Plenty of errors slip into human medical notes, but AI can actually exacerbate the problem, thanks to a well-documented phenomenon known as automation bias, where complacency leads people to miss errors in a system that's right most of the time. Even AI checking an AI's work is still imperfect, he says. 'When we deal with medical care, imperfect can feel intolerable.' 'Maybe other people are like, 'If we can get as high as a human, we're good enough.' I don't buy that for a second' 'You know the driverless car analogy, 'Hey, it's driven me so well so many times, I'm going to go to sleep at the wheel.' It's like, 'Whoa, whoa, wait a minute, when your or somebody else's life is on the line, maybe that's not the right way to do this,'' Chen says, adding, 'I think there's a lot of help and benefit we get, but also very obvious mistakes will happen that don't need to happen if we approach this in a more deliberate way.' Requiring AI to work perfectly without human intervention, Chen says, could mean 'we'll never get the benefits out of it that we can use right now. On the other hand, we should hold it to as high a bar as it can achieve. And I think there's still a higher bar it can and should reach for.' Getting second opinions from multiple, real people remains vital. That said, Google's paper had more than 50 authors, and it was reviewed by medical professionals before publication. It's not clear exactly why none of them caught the error; Google did not directly answer a question about why it slipped through. Dr. Michael Pencina, chief data scientist at Duke Health, tells The Verge he's 'much more likely to believe' the Med-Gemini error is a hallucination than a typo, adding, 'The question is, again, what are the consequences of it?' The answer, to him, rests in the stakes of making an error — and with healthcare, those stakes are serious. 'The higher-risk the application is and the more autonomous the system is ... the higher the bar for evidence needs to be,' he says. 'And unfortunately we are at a stage in the development of AI that is still very much what I would call the Wild West.' 'In my mind, AI has to have a way higher bar of error than a human,' Providence's Shah says. 'Maybe other people are like, 'If we can get as high as a human, we're good enough.' I don't buy that for a second. Otherwise, I'll just keep my humans doing the work. With humans I know how to go and talk to them and say, 'Hey, let's look at this case together. How could we have done it differently?' What are you going to do when the AI does that?' Posts from this author will be added to your daily email digest and your homepage feed. See All by Hayden Field Posts from this topic will be added to your daily email digest and your homepage feed. See All AI Posts from this topic will be added to your daily email digest and your homepage feed. See All Features Posts from this topic will be added to your daily email digest and your homepage feed. See All Google Posts from this topic will be added to your daily email digest and your homepage feed. See All Health Posts from this topic will be added to your daily email digest and your homepage feed. See All Report Posts from this topic will be added to your daily email digest and your homepage feed. See All Science Posts from this topic will be added to your daily email digest and your homepage feed. See All Tech
Yahoo
4 hours ago
- Yahoo
Nature Methods Paper Leverages PacBio Sequencing Technology to Develop the Platinum Pedigree Benchmark, a New Standard for Accurate Characterization of Variation in the Human Genome that Improves Training for AI Models
The most comprehensive, family-based variant dataset ever published will improve variant classification using AI-based tools MENLO PARK, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced the results of a study published in Nature Methods describing a new, comprehensive truth-set of genomic variation which characterizes simple and complex variation. These improved benchmarks were used to retrain Google's DeepVariant, a popular AI-based variant calling tool, resulting in a 34% reduction in erroneously called variants. This resource (the Platinum Pedigree) was built by scientists from PacBio in collaboration with researchers at the University of Washington, the University of Utah, and several other institutions. Combining inheritance-based validation with long-read sequencing, this benchmark accurately characterizes variants, even in difficult, repeat rich regions of the genome, producing the most complete view of validated genetic variation to date. 'Comprehensive benchmarking datasets that include all variant types are foundational to progress in genomics methods development and the application of AI-driven tools, as well as to our understanding of genomic variation for both research and diagnostic purposes,' said Zev Kronenberg, lead author and Senior Manager at PacBio. 'The Platinum Pedigree benchmark doesn't just include simple variants in easy-to-sequence regions, it includes variants from across the entire genome, including regions that were previously excluded from benchmarks due to their complex nature.' The Platinum Pedigree dataset was developed using deep sequencing from three sequencing platforms across a 28-member, multi-generational family (CEPH-1463). By tracking the inheritance of genetic variants from parents to multiple children, the study confidently catalogs over 37 Mb of genetic variation segregating within the family from single nucleotide variants to large structural variants. The dataset introduces the first large pedigree-validated tandem repeat and structural variant truth sets. It also adds more than 200 million bases extending the benchmark regions to 2.77 Gb, including difficult-to-map areas such as segmental duplications and low-complexity regions. A Benchmark Built for the Dark Genome As a demonstration of the value of improved benchmarks to improve AI and ML methods, the researchers retrained Google's DeepVariant - a popular software tool that employs deep learning to identify genetic variants - using the Platinum Pedigree benchmark data. This updated DeepVariant model reduced errors by up to 34% genome-wide, including even higher gains in the most challenging regions of the genome. 'This benchmark pushes accuracy where it matters most,' said Michael Eberle, senior author and Vice President of Computational Biology at PacBio. 'It enables better evaluation of variant calling pipelines and accelerates the development of methods that finally reach the full genome, including some of the complex regions that are important for human health.' A New Standard for Clinical and Population Genomics The Platinum Pedigree benchmark is freely available and already being used by scientists to develop new sequence analysis tools and validate clinical sequencing workflows. It also provides a roadmap for future benchmarking efforts, especially those involving more complete genomes like T2T-CHM13. The full dataset, analysis code, and pipelines are publicly available at: About the Study The study, 'The Platinum Pedigree: A long-read benchmark for genetic variants,' was published in Nature Methods on August 4, 2025. It was led by scientists at PacBio, the University of Washington, and University of Utah, with support from the NIH and Howard Hughes Medical Institute. About PacBio PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit and follow @PacBio. PacBio products are provided for Research Use Only. Not for use in diagnostic procedures. Forward Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the uses, advantages, quality or performance of, or the benefits or expected benefits of using, PacBio products or technologies, including in connection with the Platinum Pedigree dataset, its potential to enable better evaluation of variant calling pipelines and accelerate development methods that reach the full genome, and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties that could cause actual outcomes and results to differ materially from currently anticipated results. These risks include, but are not limited to, rapidly changing technologies and extensive competition in genomic sequencing; unanticipated increases in costs or expenses; and other risks associated with general macroeconomic conditions and geopolitical instability. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption 'Risk Factors.' These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available Contacts Investors and Media:Todd Friedmanir@ Media: ir@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Upturn
4 hours ago
- Business Upturn
Noom Launches Microdose GLP-1 Program, Enabling Weight Loss Without the Side Effects and Priced at $119 to Start, Including Medication and Microhabits Program
70% of Noom members receiving microdoses of GLP-1 with lifestyle support report no side effects, while experiencing significant weight loss and overall health gains The program addresses all three major barriers to bending the obesity curve in the US: excessive US prices of medication, medication side effects, and sustainable lifestyle change NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) — Noom , the leading digital healthcare company committed to chronic disease prevention and empowering people to live better longer, today announced the launch of the Noom Microdose GLP-1Rx Program, a groundbreaking offering designed to unlock weight loss and long-term health benefits while minimizing side effects through personalized microdoses of GLP-1 medication, when clinically appropriate. The Microdose GLP-1Rx Program is priced at $119 to start, followed by $199 per month, which includes medication, if prescribed, and Noom's powerful GLP-1 Companion, providing clinical care, coaching, and a personalized healthy habits program. The US obesity rate, after decades of unstoppable growth, has at last started to plateau, but at a level that continues to lead the developed world. The US rate of obesity stands at more than 40% versus the UK at 26%, Germany at 23%, and France at 10%. Meanwhile, GLP-1 medications cost as much as 5x more in the US than in these same countries. Three core barriers prevent broader and faster progress: medication cost, medication side effects, and the lack of sustainable behavior change. Noom's Microdose GLP-1Rx Program directly addresses each of these three barriers, to help meaningfully bend the obesity curve. Only affordable GLP-1s and Behavior Change will bend this curve. Noom's physician-designed program employs a 'low and slow' titration approach with microdoses that are a fraction of conventional maintenance doses. Noom's data has shown that members on microdoses are far less likely to have destabilizing side effects. In fact, 70% of Noom members receiving microdoses report no side effects at all. At the same time, members achieve up to 11 pounds of weight loss in 30 days and up to 17 pounds in 60 days at microdose dosages. Meanwhile, studies indicate the vast majority–more than 70%–of patients on standardized protocols experience side effects . 'In the Microdose GLP-1Rx Program, we set out to virtually eliminate side effects for the vast majority, so that more than 70% of people would encounter no side effects. In both my clinical experience and evidence in published studies, it is clear that many people discontinue GLP-1 treatment because of side effects,' said Dr. Jeffrey Egler, Chief Medical Officer at Noom. 'The Noom Microdose GLP-1Rx Program was designed to address this issue by introducing GLP-1s gradually and sustaining them at a microdose level, as part of a larger holistic behavior change platform, which we call our GLP-1 Companion. This approach helps more patients stay on the treatment, experience the full health benefits of these medications, and make real progress in reducing obesity and overweight rates in the United States.' Noom's Microdose GLP-1Rx Program is based on scientific principles: Self-efficacy boosts success with healthy habits . GLP-1 medication makes it easier to adopt healthy habits, while healthy habits improve health outcomes. Members who engage with Noom's GLP-1 Companion achieve 10% weight loss by month 4 at twice the rate compared to those who are not engaged. Noom members on GLP-1s actually log more meals, weigh in more often, and log more exercise by their second month than those on Noom without a GLP-1. . GLP-1 medication makes it easier to adopt healthy habits, while healthy habits improve health outcomes. Members who engage with Noom's GLP-1 Companion achieve 10% weight loss by month 4 at twice the rate compared to those who are not engaged. Noom members on GLP-1s actually log more meals, weigh in more often, and log more exercise by their second month than those on Noom without a GLP-1. Strong weight loss outcomes at lower doses are both achievable and well established in the literature. A 2,700‑person real‑world study presented at the 2025 European Congress on Obesity showed an average 16% weight‑loss over 64 weeks at microdose levels of semaglutide. Meanwhile, another study in The New England Journal of Medicine shows just 33% of the dose of one popular GLP-1 drove 72% of the weight loss at week 72 with a lower side effect profile. A 2,700‑person real‑world study presented at the 2025 European Congress on Obesity showed an average of semaglutide. Meanwhile, another study in shows just with a lower side effect profile. The benefits from GLP-1s extend beyond weight . Recent analyses presented at the National Lipid Association's 2025 Scientific Sessions highlighted cardiovascular, renal, and metabolic gains from GLP‑1s that appear partly independent of the amount of weight loss. Other studies show a similar impact on inflammatory markers independent of weight loss.. Meanwhile, other studies demonstrate a reduction in compulsive behaviors like drinking and gambling . Taken together, the evidence is clear: microdoses of GLP-1 paired with microhabits can unlock outsized health benefits. What is a Microdose? Noom defines a microdose as a dose of medication that is a fraction – 25% or less – of the typically prescribed maintenance dose. Noom's microdose dosing schedule is not one-size-fits-all. It accesses doses lower than the usual starter doses as well as additional doses up to 25% of the standard maintenance dose. Within that band, the exact dosage schedule is established one member at a time: our physician-prescribed protocol, aided by Noom's SmartDose experience, guides members to the lowest dose that achieves health goals. Factors influencing that decision include BMI, weight loss speed, side effect profile, and other health data. 'Noom has a unique, proprietary dataset that permits the level of deep personalization that our program deploys,' continued Dr. Jeffrey Egler. 'The Noom program has comprehensive data on patient health, injection dates, side effects, and weight-loss speed, and we bring that data to bear to personalize the dosing to maximize outcomes and adherence not just to the medication, but to our Noom microhabits program.' While many eligible GLP-1 users are deterred from starting medication due to fear of incurring side effects, others are challenged by high medication costs. Among those who do start using GLP-1s, over 50% stop due to costs , and as many as 36% stop due to side effects . Noom's Microdose GLP-1Rx Program bridges this gap by offering a more personalized, tolerable path to treatment. It is built on a guiding principle of using the lowest effective dose first. Rather than increasing medication on a fixed schedule, Noom's physician-designed protocol adjusts dosing based on each patient's individual progress and response. This approach enables personalized care that supports meaningful weight loss while minimizing side effects and helping more people adhere to the treatment. GLP-1s and Weight Loss Accessibility – Solving Today's High-Priced Drug Crisis GLP-1 medications continue to be significantly more affordable around the world than in the United States. Popular GLP-1 medications are priced around $99 a month in many developed nations, but at $499 a month to cash-pay patients in the United States. Cost is a major barrier to accessibility in the US, where the price of medications and healthcare services are often much higher than internationally. Noom's accessibly priced Microdose GLP-1Rx Program, starting at $119, builds on the company's advocacy efforts on behalf of patients in the US. In April 2025, Noom sponsored a back cover advertisement in the The Wall Street Journal calling for the creation of a High-Priced Drug List by HHS. The High-Priced Drug List is a market-based solution enabling competition from the country's 503A and 503B pharmacies when medications are priced higher in the United States compared to other developed countries. In addition to the launch of Noom's Microdose GLP-1Rx Program, on Wednesday, July 30th, at an event at The White House, Noom pledged to make available a free tier of Noom to all Americans – regardless of income or BMI. The free tier will launch before the end of the summer and deliver a personalized experience focused on building healthy habits in nutrition, physical activity, and stress reduction. 'Medication alone will not end the obesity epidemic. Lifestyle change is essential,' said Cook. 'By offering a no-cost way for anyone to build healthy habits with Noom, we can reach millions more Americans with the tools to help them live better longer. Pairing that with our new microdose GLP-1 program will help bend the curve on obesity rates in the United States.' Noom Microdose GLP-1Rx Program includes: Microdose GLP-1 medication, if prescribed Full access to the Noom GLP-1 Companion behavior and microhabits program 24/7 access to message doctors and care coordinators Noom premium 1:1 health coaching Prescription home delivery Pricing: $119 to start and then $199 per month Looking Ahead to Longevity 'GLP-1s with Noom's microhabit program represent a modern treatment for the ills of modernity,' said Cook. 'We help people sustain a healthy weight in a food environment engineered for dopamine-hits and excess consumption. By helping people limit compulsive eating and drinking, motivate movement, and reduce chronic inflammation, which we know GLP-1s can do, we promote a higher quality life.' 'The latest science demonstrates that we should be thinking about GLP-1 medication differently,' said Dr. Jeffrey Egler. 'GLP-1s are no longer only useful for weight loss and diabetes – they are critical for building metabolic resilience and reducing inflammation, making them a powerful component of whole-person, lasting health. For our patients, we see GLP-1s as the first step in an extraordinary journey to true vitality.' The Microdose GLP-1Rx Program is available to Americans in 45 states at the following link: About Noom: Noom is the leading whole-person health platform, combining personalized medication with psychology and habit science to help people take control of their metabolic health, weight, and longevity. Noom Health partners with top health plans and employers to offer a suite of solutions, including Noom Med, Noom Weight, Noom GLP-1 Companion, and Noom Diabetes Management and Diabetes Prevention Program to millions. Founded on a mission to empower everyone everywhere to live better longer, Noom has received multiple National Institute of Health grants and was the first mobile app recognized by the CDC as a certified diabetes prevention program. With offices in New York City and Princeton, NJ, Noom has been named one of Inc.'s Best Places to Work, Quartz's Best Workplaces for Remote Workers, and Fortune's Best Workplaces in Technology. Learn more at , subscribe to our blog , or follow us on Twitter and LinkedIn . Contact:Brandyn Bissinger [email protected]